tivantinib   Click here for help

GtoPdb Ligand ID: 7948

Synonyms: ARQ-197 | ARQ197
PDB Ligand
Compound class: Synthetic organic
Comment: Tivantinib is an allosteric inhibitor of c-MET kinase (hepatocyte growth factor receptor), with antineoplastic potential [5].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 66.89
Molecular weight 369.15
XLogP 4.02
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES O=C1NC(=O)C(C1c1c[nH]c2c1cccc2)c1cn2c3c1cccc3CCC2
Isomeric SMILES O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2c1cccc2)c1cn2c3c1cccc3CCC2
InChI InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1
InChI Key UCEQXRCJXIVODC-PMACEKPBSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. (2003)
Met, metastasis, motility and more.
Nat Rev Mol Cell Biol, 4 (12): 915-25. [PMID:14685170]
2. Boccaccio C, Comoglio PM. (2006)
Invasive growth: a MET-driven genetic programme for cancer and stem cells.
Nat Rev Cancer, 6 (8): 637-45. [PMID:16862193]
3. Danilkovitch-Miagkova A, Zbar B. (2002)
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.
J Clin Invest, 109 (7): 863-7. [PMID:11927612]
4. Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, Engelman JA, Fujita N. (2013)
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
Cancer Res, 73 (10): 3087-96. [PMID:23598276]
5. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ. (2010)
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.
Mol Cancer Ther, 9 (6): 1544-53. [PMID:20484018]
6. Rimassa L, Bruix J, Broggini M, Santoro A. (2013)
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter.
Clin Cancer Res, 19 (15): 4290. [PMID:23766362]
7. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S et al.. (2011)
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
J Clin Oncol, 29 (24): 3307-15. [PMID:21768463]